Hansa Biopharma and SERB have entered a licensing agreement worth €115 million for the development and commercialisation of a treatment for kidney transplant patients. Idefirix (imlifidase) is a first-in-class treatment that targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by the European Commission for the […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!